Specifically, the genetic or pharmaceutical inhibition of SGK1 directly inactivates cardiomyocyte sodium channel currents [44], or indirectly rescues obesity or AngII-induced AF by reducing myocardial fibrosis and inflammation [35, 45, 46]. Here, SGK1 is linked to fibrosis.